Patents by Inventor Jaime Acquaviva

Jaime Acquaviva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED CANCER TREATMENT BY HSP90 INHIBITORS GANETESPIB AND NVP-AUY922
    Publication number: 20160324863
    Abstract: Methods of treating certain cancers with ganetespib or NVP-AUY922 are disclosed. Also provided are methods of treating cancer wherein the cancer has an FGFR3 mutation and/or a low level expression of UGT1A, and/or a low level expression of UGT1A9 and/or UGT1A10. Also provided are methods of treating cancer with a mutation in FGFR3 and/or a low level expression of UGT1A, and/or a low level expression of UGT1A9 and/or UGTIA10, with ganetespib or NVP-AUY922, in combination with an FGFR3 inhibitor such as BGJ398 and AZD4547.
    Type: Application
    Filed: January 16, 2015
    Publication date: November 10, 2016
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Jaime Acquaviva, David Proia
  • Combination therapy of HSP90 inhibitors with BRAF inhibitors
    Patent number: 9402831
    Abstract: A pharmaceutical combination comprising a BRAF inhibitor, and an Hsp90 inhibitor according to the following formulae (I): or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables are defined therein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: August 2, 2016
    Assignee: Synta Pharmaceutical Corp.
    Inventors: David Proia, Jaime Acquaviva
  • TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS
    Publication number: 20150099721
    Abstract: A method for treating cancer with a mutation in ROS or RET, comprising identifying a subject with a cancer with a mutation in ROS or RET, and administering to the subject an effective amount of a compound according to formulae (I) OR (la) or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein.
    Type: Application
    Filed: May 10, 2013
    Publication date: April 9, 2015
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Jaime Acquaviva, Suqin He, David Proia
  • COMBINATION THERAPY OF HSP90 INHIBITORS WITH BRAF INHIBITORS
    Publication number: 20140256680
    Abstract: A pharmaceutical combination comprising a BRAF inhibitor, and an Hsp90 inhibitor according to the following formulae (I): or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables are defined therein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Application
    Filed: November 14, 2012
    Publication date: September 11, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: David Proia, Jaime Acquaviva
  • COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MEK INHIBITORS
    Publication number: 20140228418
    Abstract: A pharmaceutical composition comprising an MEK inhibitor, and an Hsp90 inhibitor according to the following formulae (I) or (Ia) or tautomers or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein.
    Type: Application
    Filed: May 22, 2012
    Publication date: August 14, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: David Proia, Jaime Acquaviva